Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on April 3, 2008
A more recent version of this article appeared on January 1, 2008
Neuro Oncol 2008, DOI:10.1215/15228517-2008-007
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow All Versions of this Article:
10/3/348    most recent
15228517-2008-007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knifed, E.
Right arrow Articles by Bernstein, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Copyright 2008 by the Society for Neuro-Oncology

Received September 4, 2007
Accepted November 30, 2007

Clinical Investigations

Patients' perception of the informed consent process for neurooncology clinical trials

Eva Knifed 1, Nir Lipsman 1, Warren Mason 1, Mark Bernstein 1*

1 Division of Neurosurgery, Toronto Western Hospital, University Health Network, and Division of Neurology, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada

* To whom correspondence should be addressed. E-mail: mark.bernstein{at}uhn.on.ca.


   Abstract

The informed consent process is a cornerstone of modern medical research. This study was conducted to explore the process in the context of neurooncology clinical trials. Qualitative methodology and analysis were used on open-ended, face-to-face interviews conducted with 21 patients. Six comprehensive themes emerged: (1) general understanding of the objectives and purpose of clinical trials was good, (2) recall of risks was low, (3) patients did not believe that their care would be compromised by forgoing the clinical trial, (4) patients felt participation was voluntary and free of coercion, (5) patients would not have withdrawn from the trial in the event of complications, and (6) patients were satisfied with the informed consent process. Informed consent is a dynamic process; when appropriately executed, it can be a powerful safeguard protecting patient autonomy. If sufficient time is allowed to deliberate participation and ample opportunity is provided for information sharing and disclosure, researchers can be confident that participants are knowledgeable about the trial and aware of their rights.

Key Words: brain tumor, clinical trials, informed consent, neurooncology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2008 by Society for Neuro-Oncology